BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38363493)

  • 1. Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors.
    Arnold LM; Hoshina Y; Lee H; Colman H; Mendez J
    J Neurooncol; 2024 Mar; 167(1):211-217. PubMed ID: 38363493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
    Awad M; Sierra CM; Mesghali E; Bahjri K
    J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
    J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
    Geerlinks AV; Campigotto A; Science M; Gupta S
    Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
    Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
    Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
    Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
    Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
    Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
    Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
    Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
    BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
    Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
    Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
    Avino LJ; Naylor SM; Roecker AM
    Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumocystis jirovecii Pneumonia Prophylaxis with Intravenous Pentamidine in Adult Allogeneic Hematopoietic Stem Cell Transplant Patients.
    McCollam S; Lewis JS; Bubalo J; Diaz A
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0083322. PubMed ID: 36214573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients: A single-centre retrospective study.
    Kato H; Hagihara M; Asai N; Mikamo H; Iwamoto T
    Int J Antimicrob Agents; 2024 May; 63(5):107151. PubMed ID: 38508538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
    Carr A; Tindall B; Penny R; Cooper DA
    AIDS; 1992 Feb; 6(2):165-71. PubMed ID: 1558714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
    Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
    J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
    Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
    Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of intravenous pentamidine for Pneumocystis jirovecii pneumonia prophylaxis in adult patients with hematologic malignancies-its utility during respiratory virus pandemics.
    Liew YX; Ho AYL; Wong GC; Chung SJ; Tan TT; Tan BH
    Int J Infect Dis; 2024 Jun; 143():107059. PubMed ID: 38615824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia.
    Nazir HF; Elshinawy M; AlRawas A; Khater D; Zadjaly S; Wali Y
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):203-208. PubMed ID: 28234744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts' Opinion and Systematic Review from the Literature.
    Navarro M; Allemang-Trivalle A; Leducq S; Jonville-Bera AP; Maurier A; Zejli T; Edée AE; Harchaoui E; Giraudeau B; Maruani A
    Dermatology; 2023; 239(6):942-951. PubMed ID: 37793356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.
    Quinn M; Fannin JT; Sciasci J; Bragg A; Campbell PK; Carias D; Crews KR; Gregornik D; Jeha S; Maron G; Pauley JL; Swanson HD; Wolf J; Greene W
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.